Benchmark Upgrades OncoCyte Corp (OCX) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts OCX Hot Sheet
Price: $3.20 --0%
Rating Summary:
4 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
4 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Benchmark analyst Bruce Jackson upgraded OncoCyte Corp (NYSE: OCX) from Speculative Buy to Buy with a price target of $6.00.
For an analyst ratings summary and ratings history on OncoCyte Corp click here. For more ratings news on OncoCyte Corp click here.
Shares of OncoCyte Corp closed at $2.60 yesterday.
You May Also Be Interested In
- JPMorgan Upgrades Indusind Bank Ltd (IIB:IN) to Neutral
- Raymond James Upgrades Hess Midstream Partners LP (HESM) to Outperform
- Scotiabank Upgrades Rumo SA (RAIL3:BZ) to Sector Outperform
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
